TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:TAK - US8740602052 - ADR
15.59 USD
-0.04 (-0.26%)
15.5 USD
-0.09 (-0.58%)
Overall TAK gets a fundamental rating of 5 out of 10. We evaluated TAK against 191 industry peers in the Pharmaceuticals industry. TAK scores excellent on profitability, but there are concerns on its financial health. TAK has a valuation in line with the averages, but on the other hand it scores bad on growth. TAK also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
In the past year TAK was profitable.
In the past year TAK had a positive cash flow from operations.
Each year in the past 5 years TAK has been profitable.
Each year in the past 5 years TAK had a positive operating cash flow.
1.2 Ratios
TAK has a Return On Assets of 0.23%. This is in the better half of the industry: TAK outperforms 78.01% of its industry peers.
TAK has a better Return On Equity (0.46%) than 79.58% of its industry peers.
TAK has a better Return On Invested Capital (1.87%) than 79.06% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for TAK is significantly below the industry average of 12.85%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.23% | ||
| ROE | 0.46% | ||
| ROIC | 1.87% |
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.62%
ROIC(5y)2.55%
1.3 Margins
With a decent Profit Margin value of 0.75%, TAK is doing good in the industry, outperforming 78.01% of the companies in the same industry.
In the last couple of years the Profit Margin of TAK has grown nicely.
TAK's Operating Margin of 8.46% is amongst the best of the industry. TAK outperforms 80.10% of its industry peers.
TAK's Operating Margin has improved in the last couple of years.
With a decent Gross Margin value of 64.60%, TAK is doing good in the industry, outperforming 74.35% of the companies in the same industry.
In the last couple of years the Gross Margin of TAK has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.46% | ||
| PM (TTM) | 0.75% | ||
| GM | 64.6% |
OM growth 3Y-8.47%
OM growth 5Y6.13%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), TAK is creating some value.
The number of shares outstanding for TAK has been increased compared to 1 year ago.
Compared to 5 years ago, TAK has more shares outstanding
Compared to 1 year ago, TAK has an improved debt to assets ratio.
2.2 Solvency
TAK has an Altman-Z score of 1.20. This is a bad value and indicates that TAK is not financially healthy and even has some risk of bankruptcy.
TAK has a Altman-Z score (1.20) which is comparable to the rest of the industry.
The Debt to FCF ratio of TAK is 5.04, which is a neutral value as it means it would take TAK, 5.04 years of fcf income to pay off all of its debts.
TAK has a Debt to FCF ratio of 5.04. This is amongst the best in the industry. TAK outperforms 82.72% of its industry peers.
A Debt/Equity ratio of 0.61 indicates that TAK is somewhat dependend on debt financing.
TAK's Debt to Equity ratio of 0.61 is on the low side compared to the rest of the industry. TAK is outperformed by 68.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 5.04 | ||
| Altman-Z | 1.2 |
ROIC/WACC1.16
WACC1.61%
2.3 Liquidity
A Current Ratio of 1.36 indicates that TAK should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.36, TAK is doing worse than 73.82% of the companies in the same industry.
A Quick Ratio of 0.76 indicates that TAK may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.76, TAK is doing worse than 84.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.76 |
3. Growth
3.1 Past
The earnings per share for TAK have decreased strongly by -88.38% in the last year.
The Earnings Per Share has been growing by 19.20% on average over the past years. This is quite good.
TAK shows a decrease in Revenue. In the last year, the revenue decreased by -2.84%.
The Revenue has been growing slightly by 6.84% on average over the past years.
EPS 1Y (TTM)-88.38%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%-112.87%
Revenue 1Y (TTM)-2.84%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%-5.38%
3.2 Future
TAK is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 43.97% yearly.
The Revenue is expected to decrease by -0.03% on average over the next years.
EPS Next Y83.65%
EPS Next 2Y68.19%
EPS Next 3Y43.97%
EPS Next 5YN/A
Revenue Next Year-1.77%
Revenue Next 2Y-0.66%
Revenue Next 3Y-0.03%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 222.71, which means the current valuation is very expensive for TAK.
75.39% of the companies in the same industry are more expensive than TAK, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.51. TAK is valued rather expensively when compared to this.
A Price/Forward Earnings ratio of 25.30 indicates a quite expensive valuation of TAK.
Compared to the rest of the industry, the Price/Forward Earnings ratio of TAK indicates a somewhat cheap valuation: TAK is cheaper than 74.87% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.13. TAK is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 222.71 | ||
| Fwd PE | 25.3 |
4.2 Price Multiples
87.43% of the companies in the same industry are more expensive than TAK, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of TAK indicates a rather cheap valuation: TAK is cheaper than 93.72% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.37 | ||
| EV/EBITDA | 10.35 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates TAK does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of TAK may justify a higher PE ratio.
A more expensive valuation may be justified as TAK's earnings are expected to grow with 43.97% in the coming years.
PEG (NY)2.66
PEG (5Y)11.6
EPS Next 2Y68.19%
EPS Next 3Y43.97%
5. Dividend
5.1 Amount
TAK has a Yearly Dividend Yield of 4.12%, which is a nice return.
Compared to an average industry Dividend Yield of 0.61, TAK pays a better dividend. On top of this TAK pays more dividend than 97.38% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.00, TAK pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.12% |
5.2 History
The dividend of TAK has a limited annual growth rate of 1.18%.
TAK has been paying a dividend for at least 10 years, so it has a reliable track record.
TAK has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)1.18%
Div Incr Years2
Div Non Decr Years3
5.3 Sustainability
TAK pays out 935.06% of its income as dividend. This is not a sustainable payout ratio.
The dividend of TAK is growing, but earnings are growing more, so the dividend growth is sustainable.
DP935.06%
EPS Next 2Y68.19%
EPS Next 3Y43.97%
15.59
-0.04 (-0.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners46.91%
Inst Owner Change8.68%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap49.25B
Revenue(TTM)4.42T
Net Income(TTM)33.08B
Analysts73.68
Price Target16.52 (5.97%)
Short Float %0.37%
Short Ratio4.12
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.12% |
Yearly Dividend0.62
Dividend Growth(5Y)1.18%
DP935.06%
Div Incr Years2
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-41.49%
Min EPS beat(2)-121.92%
Max EPS beat(2)38.94%
EPS beat(4)1
Avg EPS beat(4)-35.42%
Min EPS beat(4)-121.92%
Max EPS beat(4)38.94%
EPS beat(8)4
Avg EPS beat(8)-31.47%
EPS beat(12)6
Avg EPS beat(12)-33.69%
EPS beat(16)7
Avg EPS beat(16)-40.61%
Revenue beat(2)0
Avg Revenue beat(2)-6.4%
Min Revenue beat(2)-6.76%
Max Revenue beat(2)-6.04%
Revenue beat(4)0
Avg Revenue beat(4)-3.84%
Min Revenue beat(4)-6.76%
Max Revenue beat(4)-0.48%
Revenue beat(8)4
Avg Revenue beat(8)3.03%
Revenue beat(12)7
Avg Revenue beat(12)3.44%
Revenue beat(16)11
Avg Revenue beat(16)3.69%
PT rev (1m)1.64%
PT rev (3m)-6.4%
EPS NQ rev (1m)16.95%
EPS NQ rev (3m)30.09%
EPS NY rev (1m)-13.53%
EPS NY rev (3m)-18.71%
Revenue NQ rev (1m)1.76%
Revenue NQ rev (3m)1.74%
Revenue NY rev (1m)-0.55%
Revenue NY rev (3m)-0.72%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 222.71 | ||
| Fwd PE | 25.3 | ||
| P/S | 1.75 | ||
| P/FCF | 8.37 | ||
| P/OCF | 6.43 | ||
| P/B | 1.08 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.35 |
EPS(TTM)0.07
EY0.45%
EPS(NY)0.62
Fwd EY3.95%
FCF(TTM)1.86
FCFY11.95%
OCF(TTM)2.42
OCFY15.55%
SpS8.92
BVpS14.41
TBVpS-3.23
PEG (NY)2.66
PEG (5Y)11.6
Graham Number4.76
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.23% | ||
| ROE | 0.46% | ||
| ROCE | 3.03% | ||
| ROIC | 1.87% | ||
| ROICexc | 1.99% | ||
| ROICexgc | 8.07% | ||
| OM | 8.46% | ||
| PM (TTM) | 0.75% | ||
| GM | 64.6% | ||
| FCFM | 20.88% |
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.62%
ROIC(5y)2.55%
ROICexc(3y)2.76%
ROICexc(5y)2.73%
ROICexgc(3y)14.61%
ROICexgc(5y)14.15%
ROCE(3y)4.25%
ROCE(5y)4.14%
ROICexgc growth 3Y-6.2%
ROICexgc growth 5Y8.09%
ROICexc growth 3Y-3.88%
ROICexc growth 5Y10.72%
OM growth 3Y-8.47%
OM growth 5Y6.13%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
F-Score6
Asset Turnover0.31
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 5.04 | ||
| Debt/EBITDA | 3.9 | ||
| Cap/Depr | 37.3% | ||
| Cap/Sales | 6.28% | ||
| Interest Coverage | 3.04 | ||
| Cash Conversion | 107.4% | ||
| Profit Quality | 2788.5% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.76 | ||
| Altman-Z | 1.2 |
F-Score6
WACC1.61%
ROIC/WACC1.16
Cap/Depr(3y)69.03%
Cap/Depr(5y)56.25%
Cap/Sales(3y)11.53%
Cap/Sales(5y)9.44%
Profit Quality(3y)309.71%
Profit Quality(5y)308.48%
High Growth Momentum
Growth
EPS 1Y (TTM)-88.38%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%-112.87%
EPS Next Y83.65%
EPS Next 2Y68.19%
EPS Next 3Y43.97%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.84%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%-5.38%
Revenue Next Year-1.77%
Revenue Next 2Y-0.66%
Revenue Next 3Y-0.03%
Revenue Next 5YN/A
EBIT growth 1Y-31.07%
EBIT growth 3Y-0.52%
EBIT growth 5Y13.39%
EBIT Next Year435.35%
EBIT Next 3Y77.31%
EBIT Next 5YN/A
FCF growth 1Y613.62%
FCF growth 3Y-8.86%
FCF growth 5Y9.4%
OCF growth 1Y24.54%
OCF growth 3Y-2%
OCF growth 5Y9.54%
TAKEDA PHARMACEUTIC-SP ADR / TAK FAQ
What is the fundamental rating for TAK stock?
ChartMill assigns a fundamental rating of 5 / 10 to TAK.
What is the valuation status for TAK stock?
ChartMill assigns a valuation rating of 5 / 10 to TAKEDA PHARMACEUTIC-SP ADR (TAK). This can be considered as Fairly Valued.
What is the profitability of TAK stock?
TAKEDA PHARMACEUTIC-SP ADR (TAK) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for TAK stock?
The Price/Earnings (PE) ratio for TAKEDA PHARMACEUTIC-SP ADR (TAK) is 222.71 and the Price/Book (PB) ratio is 1.08.
How financially healthy is TAKEDA PHARMACEUTIC-SP ADR?
The financial health rating of TAKEDA PHARMACEUTIC-SP ADR (TAK) is 3 / 10.